Citi lowered the firm’s price target on Rain Oncology to $1 from $1.50 and keeps a Neutral rating on the shares. The analyst updated biotechnology models post the Q2 reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RAIN: